Our passion for scientific discovery led to two FDA-approved treatments for neurological conditions.
Neurocrine Biosciences/AbbVie Collaboration
After discovering and developing elagolix through Phase 2 studies in endometriosis, we out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix. AbbVie launched ORILISSA® (elagolix tablets) in the United States and Canada in August and November 2018, respectively.